BioCentury
ARTICLE | Company News

Alnylam provides pipeline update

December 11, 2015 2:29 AM UTC

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) said it expects 10 "major clinical data readouts" next year and expects to have data from its first Phase III trial, a study of amyloidosis candidate patisiran ( ALN-TTR02), by YE17. The update came at an R&D day on Thursday, where Alnylam provided guidance on its ongoing clinical-stage programs and discussed its Alnylam 2020 plan.

The Phase III readout will come from the APOLLO trial, which is evaluating patisiran to treat familial amyloid cardiomyopathy (FAC), a form of transthyretin (TTR)-mediated amyloidosis (ATTR). Patisiran is an IV RNAi therapeutic targeting the TTR gene. ...